Publication:
Bone marrow activation in response to metabolic syndrome and early atherosclerosis

dc.contributor.authorDevesa, Ana
dc.contributor.authorLobo-González, Manuel
dc.contributor.authorMartínez-Milla, Juan
dc.contributor.authorOliva, Belén
dc.contributor.authorGarcía-Lunar, Inés
dc.contributor.authorMastrangelo, Annalaura
dc.contributor.authorEspaña, Samuel
dc.contributor.authorSanz, Javier
dc.contributor.authorMendiguren, José M
dc.contributor.authorBueno, Hector
dc.contributor.authorFuster, Jose J.
dc.contributor.authorAndres, Vicente
dc.contributor.authorFernández-Ortiz, Antonio
dc.contributor.authorSancho, David
dc.contributor.authorFernández-Friera, Leticia
dc.contributor.authorSanchez-Gonzalez, Javier
dc.contributor.authorRossello, Xavier
dc.contributor.authorIbáñez, Borja
dc.contributor.authorFuster, Valentin
dc.contributor.funderBanco Santander
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
dc.contributor.funderUnión Europea. Comisión Europea
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderFundación ProCNIC
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.date.accessioned2022-11-15T15:27:33Z
dc.date.available2022-11-15T15:27:33Z
dc.date.issued2022
dc.description.abstractAims: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. Methods and results: Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). Conclusion: In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe PESA study is funded by the CNIC and Santander Bank. The present study was partially funded by an intramural grant CNIC-Severo Ochoa to D.S. and B.I. B.I. is supported by the European Commission (H2020-HEALTH 945118 and ERC-CoG 819775). The CNIC is supported by the ISCIII, the Ministry of Science and Innovation, and the Pro CNIC Foundation. CNIC is a Severo Ochoa Center of Excellence (CEX2020-001041-S).es_ES
dc.format.number19es_ES
dc.format.page1809-1828es_ES
dc.format.volume43es_ES
dc.identifier.citationEur Heart J . 2022 May 14;43(19):1809-1828es_ES
dc.identifier.doi10.1093/eurheartj/ehac102es_ES
dc.identifier.e-issn1522-9645es_ES
dc.identifier.journalEuropean heart journales_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/18038
dc.identifier.pubmedID35567559es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15158
dc.identifier.wos768442400001
dc.language.isoenges_ES
dc.publisherOxford University Press
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/H2020-HEALTHes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/ERC-CoG 819775es_ES
dc.relation.publisherversion10.1093/eurheartj/ehac102es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.institutei+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
dc.repisalud.instituteIdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
dc.repisalud.instituteIIS-FJD - Instituto de Investigación Sanitaria Fundación Jiménez Díaz (Madrid)
dc.repisalud.instituteIdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
dc.repisalud.orgCNICCNIC::Grupos de investigación::Inmunobiologíaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBone marrow
dc.subjectMetabolic syndrome
dc.subjectPET/MRI
dc.subjectSubclinical atherosclerosis
dc.subject.decsFluorodesoxiglucosa F18
dc.subject.decsTomografía Computarizada por Tomografía de Emisión de Positrones
dc.subject.decsBiomarcadores
dc.subject.decsSíndrome Metabólico
dc.subject.decsFemenino
dc.subject.decsMasculino
dc.subject.decsTomografía de Emisión de Positrones
dc.subject.decsAterosclerosis
dc.subject.decsHumanos
dc.subject.decsPersona de Mediana Edad
dc.subject.decsInflamación
dc.subject.decsRadiofármacos
dc.subject.decsMédula ósea
dc.subject.decsPlaca Aterosclerótica
dc.subject.meshAtherosclerosises_ES
dc.subject.meshMetabolic Syndromees_ES
dc.subject.meshPlaque, Atherosclerotices_ES
dc.subject.meshBiomarkerses_ES
dc.subject.meshBone Marrowes_ES
dc.subject.meshFemalees_ES
dc.subject.meshFluorodeoxyglucose F18es_ES
dc.subject.meshHumanses_ES
dc.subject.meshInflammationes_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPositron Emission Tomography Computed Tomographyes_ES
dc.subject.meshPositron-Emission Tomographyes_ES
dc.subject.meshRadiopharmaceuticalses_ES
dc.titleBone marrow activation in response to metabolic syndrome and early atherosclerosises_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication84f7c586-4bf7-44e6-9e64-393634a36e9f
relation.isAuthorOfPublication465de6aa-7383-4ba5-b278-765f894f2c87
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublication18b88155-7fc0-4400-9fba-2aa73aa8e519
relation.isAuthorOfPublication3bb85851-071a-490a-976b-c234983847a7
relation.isAuthorOfPublication58aa2591-8084-4500-bfe4-8f2c54e398e9
relation.isAuthorOfPublicationb6428aa3-d242-4efb-a7a2-b977c3aeadd8
relation.isAuthorOfPublicationbbc835c4-284a-4845-8a6e-adf765b43cc1
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublication.latestForDiscovery84f7c586-4bf7-44e6-9e64-393634a36e9f
relation.isFunderOfPublication2302598f-47dd-49b5-a26e-ae31bf61786e
relation.isFunderOfPublication9bec53f6-b1d2-4340-9f6b-91815956d602
relation.isFunderOfPublication639cecfa-9455-4e7f-9f65-9ece17a878f0
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationef935eeb-4c46-446a-868e-66e905683e75
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication.latestForDiscovery2302598f-47dd-49b5-a26e-ae31bf61786e
relation.isPublisherOfPublication465a0b1e-d9df-4342-b738-86ffcafc4bcf
relation.isPublisherOfPublication.latestForDiscovery465a0b1e-d9df-4342-b738-86ffcafc4bcf

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Eur Heart J 2022 Bone marrow activation.pdf
Size:
1.65 MB
Format:
Adobe Portable Document Format
Description:
Artículo